#BEGIN_DRUGCARD DB03963

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C5H12AsNO2S

# Chemical_IUPAC_Name:
(2S)-2-amino-3-[(dimethylarsanyl)sulfanyl]propanoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
S-(Dimethylarsenic)Cysteine

# HET_ID:
CAS

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C5H12AsNO2S/c1-6(2)10-3-4(7)5(8)9/h4H,3,7H2,1-2H3,(H,8,9)/t4-/m1/s1

# InChI_Key:
InChIKey=UKLXSOVDMSQHMM-SCSAIBSYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3963

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
225.141

# Molecular_Weight_Mono:
224.98047074

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1R4X

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-2.1

# Predicted_LogS:
-1.5

# Predicted_Water_Solubility:
7.58e+00 g/l

# Primary_Accession_No:
DB03963

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936846

# PubChem_Substance_ID:
46508261

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00832

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
C[As](C)SC[C@@H](N)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:48 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
TLR2

# Drug_Target_1_GenBank_ID_Gene:
AF051152

# Drug_Target_1_GenBank_ID_Protein:
3132528

# Drug_Target_1_GeneCard_ID:
TLR2

# Drug_Target_1_Gene_Name:
TLR2

# Drug_Target_1_Gene_Sequence:
>2355 bp
ATGCCACATACTTTGTGGATGGTGTGGGTCCTGGGGGTCATCATCAGCCTCTCCAAGGAA
GAATCCTCCAATCAGGCTTCTCTGTCTTGTGACCGCAATGGTATCTGCAAGGGCAGCTCA
GGATCTTTAAACTCCATTCCCTCAGGGCTCACAGAAGCTGTAAAAAGCCTTGACCTGTCC
AACAACAGGATCACCTACATTAGCAACAGTGACCTACAGAGGTGTGTGAACCTCCAGGCT
CTGGTGCTGACATCCAATGGAATTAACACAATAGAGGAAGATTCTTTTTCTTCCCTGGGC
AGTCTTGAACATTTAGACTTATCCTATAATTACTTATCTAATTTATCGTCTTCCTGGTTC
AAGCCCCTTTCTTCTTTAACATTCTTAAACTTACTGGGAAATCCTTACAAAACCCTAGGG
GAAACATCTCTTTTTTCTCATCTCACAAAATTGCAAATCCTGAGAGTGGGAAATATGGAC
ACCTTCACTAAGATTCAAAGAAAAGATTTTGCTGGACTTACCTTCCTTGAGGAACTTGAG
ATTGATGCTTCAGATCTACAGAGCTATGAGCCAAAAAGTTTGAAGTCAATTCAGAATGTA
AGTCATCTGATCCTTCATATGAAGCAGCATATTTTACTGCTGGAGATTTTTGTAGATGTT
ACAAGTTCCGTGGAATGTTTGGAACTGCGAGATACTGATTTGGACACTTTCCATTTTTCA
GAACTATCCACTGGTGAAACAAATTCATTGATTAAAAAGTTTACATTTAGAAATGTGAAA
ATCACCGATGAAAGTTTGTTTCAGGTTATGAAACTTTTGAATCAGATTTCTGGATTGTTA
GAATTAGAGTTTGATGACTGTACCCTTAATGGAGTTGGTAATTTTAGAGCATCTGATAAT
GACAGAGTTATAGATCCAGGTAAAGTGGAAACGTTAACAATCCGGAGGCTGCATATTCCA
AGGTTTTACTTATTTTATGATCTGAGCACTTTATATTCACTTACAGAAAGAGTTAAAAGA
ATCACAGTAGAAAACAGTAAAGTTTTTCTGGTTCCTTGTTTACTTTCACAACATTTAAAA
TCATTAGAATACTTGGATCTCAGTGAAAATTTGATGGTTGAAGAATACTTGAAAAATTCA
GCCTGTGAGGATGCCTGGCCCTCTCTACAAACTTTAATTTTAAGGCAAAATCATTTGGCA
TCATTGGAAAAAACCGGAGAGACTTTGCTCACTCTGAAAAACTTGACTAACATTGATATC
AGTAAGAATAGTTTTCATTCTATGCCTGAAACTTGTCAGTGGCCAGAAAAGATGAAATAT
TTGAACTTATCCAGCACACGAATACACAGTGTAACAGGCTGCATTCCCAAGACACTGGAA
ATTTTAGATGTTAGCAACAACAATCTCAATTTATTTTCTTTGAATTTGCCGCAACTCAAA
GAACTTTATATTTCCAGAAATAAGTTGATGACTCTACCAGATGCCTCCCTCTTACCCATG
TTACTAGTATTGAAAATCAGTAGGAATGCAATAACTACGTTTTCTAAGGAGCAACTTGAC
TCATTTCACACACTGAAGACTTTGGAAGCTGGTGGCAATAACTTCATTTGCTCCTGTGAA
TTCCTCTCCTTCACTCAGGAGCAGCAAGCACTGGCCAAAGTCTTGATTGATTGGCCAGCA
AATTACCTGTGTGACTCTCCATCCCATGTGCGTGGCCAGCAGGTTCAGGATGTCCGCCTC
TCGGTGTCGGAATGTCACAGGACAGCACTGGTGTCTGGCATGTGCTGTGCTCTGTTCCTG
CTGATCCTGCTCACGGGGGTCCTGTGCCACCGTTTCCATGGCCTGTGGTATATGAAAATG
ATGTGGGCCTGGCTCCAGGCCAAAAGGAAGCCCAGGAAAGCTCCCAGCAGGAACATCTGC
TATGATGCATTTGTTTCTTACAGTGAGCGGGATGCCTACTGGGTGGAGAACCTTATGGTC
CAGGAGCTGGAGAACTTCAATCCCCCCTTCAAGTTGTGTCTTCATAAGCGGGACTTCATT
CCTGGCAAGTGGATCATTGACAATATCATTGACTCCATTGAAAAGAGCCACAAAACTGTC
TTTGTGCTTTCTGAAAACTTTGTGAAGAGTGAGTGGTGCAAGTATGAACTGGACTTCTCC
CATTTCCGTCTTTTTGATGAGAACAATGATGCTGCCATTCTCATTCTTCTGGAGCCCATT
GAGAAAAAAGCCATTCCCCAGCGCTTCTGCAAGCTGCGGAAGATAATGAACACCAAGACC
TACCTGGAGTGGCCCATGGACGAGGCTCAGCGGGAAGGATTTTGGGTAAATCTGAGAGCT
GCGATAAAGTCCTAG

# Drug_Target_1_General_Function:
Involved in transmembrane receptor activity

# Drug_Target_1_General_References:
10426996	Aliprantis AO, Yang RB, Mark MR, Suggett S, Devaux B, Radolf JD, Klimpel GR, Godowski P, Zychlinsky A: Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science. 1999 Jul 30;285(5428):736-9.
11081518	Xu Y, Tao X, Shen B, Horng T, Medzhitov R, Manley JL, Tong L: Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature. 2000 Nov 2;408(6808):111-5.
9435236	Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF: A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):588-93.
9596645	Chaudhary PM, Ferguson C, Nguyen V, Nguyen O, Massa HF, Eby M, Jasmin A, Trask BJ, Hood L, Nelson PS: Cloning and characterization of two Toll/Interleukin-1 receptor-like genes TIL3 and TIL4: evidence for a multi-gene receptor family in humans. Blood. 1998 Jun 1;91(11):4020-7.
9751057	Yang RB, Mark MR, Gray A, Huang A, Xie MH, Zhang M, Goddard A, Wood WI, Gurney AL, Godowski PJ: Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature. 1998 Sep 17;395(6699):284-8.

# Drug_Target_1_HGNC_ID:
HGNC:11848

# Drug_Target_1_HPRD_ID:
04323

# Drug_Target_1_ID:
2090

# Drug_Target_1_Locus:
4q32

# Drug_Target_1_Molecular_Weight:
89839

# Drug_Target_1_Name:
Toll-like receptor 2

# Drug_Target_1_Number_of_Residues:
784

# Drug_Target_1_PDB_ID:
1O77

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00560	LRR_1
PF01463	LRRCT
PF01582	TIR

# Drug_Target_1_Protein_Sequence:
>Toll-like receptor 2 precursor
MPHTLWMVWVLGVIISLSKEESSNQASLSCDRNGICKGSSGSLNSIPSGLTEAVKSLDLS
NNRITYISNSDLQRCVNLQALVLTSNGINTIEEDSFSSLGSLEHLDLSYNYLSNLSSSWF
KPLSSLTFLNLLGNPYKTLGETSLFSHLTKLQILRVGNMDTFTKIQRKDFAGLTFLEELE
IDASDLQSYEPKSLKSIQNVSHLILHMKQHILLLEIFVDVTSSVECLELRDTDLDTFHFS
ELSTGETNSLIKKFTFRNVKITDESLFQVMKLLNQISGLLELEFDDCTLNGVGNFRASDN
DRVIDPGKVETLTIRRLHIPRFYLFYDLSTLYSLTERVKRITVENSKVFLVPCLLSQHLK
SLEYLDLSENLMVEEYLKNSACEDAWPSLQTLILRQNHLASLEKTGETLLTLKNLTNIDI
SKNSFHSMPETCQWPEKMKYLNLSSTRIHSVTGCIPKTLEILDVSNNNLNLFSLNLPQLK
ELYISRNKLMTLPDASLLPMLLVLKISRNAITTFSKEQLDSFHTLKTLEAGGNNFICSCE
FLSFTQEQQALAKVLIDWPANYLCDSPSHVRGQQVQDVRLSVSECHRTALVSGMCCALFL
LILLTGVLCHRFHGLWYMKMMWAWLQAKRKPRKAPSRNICYDAFVSYSERDAYWVENLMV
QELENFNPPFKLCLHKRDFIPGKWIIDNIIDSIEKSHKTVFVLSENFVKSEWCKYELDFS
HFRLFDENNDAAILILLEPIEKKAIPQRFCKLRKIMNTKTYLEWPMDEAQREGFWVNLRA
AIKS

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-18

# Drug_Target_1_Specific_Function:
Cooperates with LY96 to mediate the innate immune response to bacterial lipoproteins and other microbial cell wall components. Acts via MyD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. May also promote apoptosis in response to lipoproteins. Recognizes mycoplasmal macrophage-activating lipopeptide-2kD (MALP-2), soluble tuberculosis factor (STF), phenol-soluble modulin (PSM) and B.burgdorferi outer surface protein A lipoprotein (OspA-L) cooperatively with TLR6

# Drug_Target_1_SwissProt_ID:
O60603

# Drug_Target_1_SwissProt_Name:
TLR2_HUMAN

# Drug_Target_1_Synonyms:
CD282 antigen
Toll-like receptor 2 precursor
Toll/interleukin 1 receptor-like protein 4

# Drug_Target_1_Theoretical_pI:
6.59

# Drug_Target_1_Transmembrane_Regions:
589-609

# Drug_Target_2_Cellular_Location:
Cytoplasmic

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
X17403

# Drug_Target_2_GenBank_ID_Protein:
1780857

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
UL80

# Drug_Target_2_Gene_Sequence:
>2127 bp
ATGACGATGGACGAGCAGCAGTCGCAGGCTGTGGCGCCGGTCTACGTGGGCGGCTTTCTC
GCCCGCTACGACCAGTCTCCGGACGAGGCCGAATTGCTGTTGCCGCGGGACGTAGTGGAG
CACTGGTTGCACGCGCAGGGCCAGGGACAGCCTTCGTTGTCGGTCGCGCTCCCGCTCAAC
ATCAACCACGACGACACGGCCGTTGTAGGACACGTTGCGGCGATGCAGAGCGTCCGCGAC
GGTCTTTTTTGCCTGGGCTGCGTCACTTCGCCCAGGTTTCTGGAGATTGTACGCCGCGCT
TCGGAAAAGTCCGAGCTGGTTTCGCGCGGGCCCGTCAGTCCGCTGCAGCCAGACAAGGTG
GTGGAGTTTCTCAGCGGCAGCTACGCCGGCCTCTCGCTCTCCAGCCGGCGCTGCGACGAC
GTGGAGGCCGCGACGTCGCTTTCGGGCTCGGAAACCACGCCGTTCAAACACGTGGCTTTG
TGCAGCGTGGGTCGGCGTCGCGGTACGTTGGCCGTGTACGGGCGCGATCCCGAGTGGGTC
ACACAGCGGTTTCCAGACCTCACGGCGGCCGACCGTGACGGGCTACGTGCACAGTGGCAG
CGCTGCGGCAGCACTGCTGTCGACGCGTCGGGCGATCCCTTTCGCTCAGACAGCTACGGC
CTGTTGGGCAACAGCGTGGACGCGCTCTACATCCGTGAGCGACTGCCCAAGCTGCGCTAC
GACAAGCAACTAGTCGGCGTGACGGAGCGCGAGTCATACGTCAAGGCGAGCGTTTCGCCT
GAGGCGGCGTGCGATATTAAAGCGGCGTCCGCCGAGCGTTCGGGCGACAGCCGCAGTCAG
GCCGCCACGCCGGCGGCTGGGGCGCGCGTTCCCTCTTCGTCCCCGTCGCCTCCAGTCGAA
CCGCCATCTCCTGTACAGCCGCCTGCGCTTCCAGCGTCGCCGTCCGTTCTTCCCGCGGAA
TCACCGCCGTCGCTTTCTCCCTCGGAGCCGGCAGAGGCGGCGTCCATGTCGCACCCTCTG
AGTGCTGCGGTTCCCGCCGCTACGGCTCCTCCAGGTGCTACCGTGGCAGGTGCGTCGCCG
GCTGTGTCGTCTCTAGCGTGGCCTCACGACGGAGTTTATTTACCCAAAGACGCTTTTTTC
TCGCTACTTGGGGCCAGTCGCTCGGCAGTGCCCGTCATGTATCCCGGCGCCGTAGCGGCC
CCTCCTTCTGCTTCGCCAGCACCGCTGCCTTTGCCGTCTTATCCCGCGTCCTACGGCGCC
CCCGTCGTGGGTTACGACCAGTTGGCGGCACGTCACTTTGCGGACTACGTGGATCCCCAT
TATCCCGGGTGGGGTCGGCGTTACGAGCCCGCGCCGTCTTTGCATCCGTCTTATCCCGTG
CCGCCGCCACCATCACCGGCCTATTACCGTCGGCGCGACTCTCCGGGCGGTATGGATGAA
CCACCGTCCGGATGGGAGCGTTACGACGGTGGTCACCGTGGTCAGTCGCAGAAGCAGCAC
CGTCACGGGGGCAGCGGCGGACACAACAAACGCCGTAAGGAAACCGCGGCGGCGTCGTCG
TCGTCCTCGGACGAAGACTTGAGTTTCCCAGGCGAGGCCGAGCACGGCCGGGCACGAAAG
CGTCTAAAAAGTCACGTCAATAGCGACGGTGGAAGTGGCGGGCACGCGGGTTCCAATCAG
CAGCAGCAACAACGTTACGATGAACTGCGGGATGCCATTCACGAGCTGAAACGCGATCTG
TTTGCTGCGCGGCAGAGTTCTACGTTACTTTCGGCGGCTCTTCCCTCTGCGGCCTCTTCC
TCCCCAACTACTACTACCGTGTGTACTCCCACCGGCGAGCTGACGAGTGGCGGAGGAGAA
ACACCCACGGCACTTCTATCCGGAGGTGCCAAGGTAGCTGAGCGCGCTCAGGCCGGCGTG
GTGAACGCCAGTTGCCGCCTCGCTACCGCGTCGGGTTCTGAGGCGGCAACGGCCGGGCCC
TCGACGGCAGGTTCTTCTTCCTGCCCGGCTAGTGTCGTGTTAGCCGCCGCTGCTGCCCAA
GCCGCCGCAGCTTCCCAGAGCCCGCCCAAAGACATGGTAGATCTGAATCGGCGGATTTTT
GTGGCTGCGCTCAATAAGCTCGAGTAA

# Drug_Target_2_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_2_General_References:
12533697	Davison AJ, Dolan A, Akter P, Addison C, Dargan DJ, Alcendor DJ, McGeoch DJ, Hayward GS: The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. J Gen Virol. 2003 Jan;84(Pt 1):17-28.
2161319	Chee MS, Bankier AT, Beck S, Bohni R, Brown CM, Cerny R, Horsnell T, Hutchison CA 3rd, Kouzarides T, Martignetti JA, et al.: Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol. 1990;154:125-69.
8805706	Tong L, Qian C, Massariol MJ, Bonneau PR, Cordingley MG, Lagace L: A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease. Nature. 1996 Sep 19;383(6597):272-5.
8805707	Qiu X, Culp JS, DiLella AG, Hellmig B, Hoog SS, Janson CA, Smith WW, Abdel-Meguid SS: Unique fold and active site in cytomegalovirus protease. Nature. 1996 Sep 19;383(6597):275-9.
8805708	Shieh HS, Kurumbail RG, Stevens AM, Stegeman RA, Sturman EJ, Pak JY, Wittwer AJ, Palmier MO, Wiegand RC, Holwerda BC, Stallings WC: Three-dimensional structure of human cytomegalovirus protease. Nature. 1996 Sep 19;383(6597):279-82.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2433

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
73852

# Drug_Target_2_Name:
Capsid protein P40

# Drug_Target_2_Number_of_Residues:
708

# Drug_Target_2_PDB_ID:
1LAY

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00716	Peptidase_S21

# Drug_Target_2_Protein_Sequence:
>Capsid protein P40 [Contains: Assemblin
MTMDEQQSQAVAPVYVGGFLARYDQSPDEAELLLPRDVVEHWLHAQGQGQPSLSVALPLN
INHDDTAVVGHVAAMQSVRDGLFCLGCVTSPRFLEIVRRASEKSELVSRGPVSPLQPDKV
VEFLSGSYAGLSLSSRRCDDVEAATSLSGSETTPFKHVALCSVGRRRGTLAVYGRDPEWV
TQRFPDLTAADRDGLRAQWQRCGSTAVDASGDPFRSDSYGLLGNSVDALYIRERLPKLRY
DKQLVGVTERESYVKASVSPEAACDIKAASAERSGDSRSQAATPAAGARVPSSSPSPPVE
PPSPVQPPALPASPSVLPAESPPSLSPSEPAEAASMSHPLSAAVPAATAPPGATVAGASP
AVSSLAWPHDGVYLPKDAFFSLLGASRSAVPVMYPGAVAAPPSASPAPLPLPSYPASYGA
PVVGYDQLAARHFADYVDPHYPGWGRRYEPAPSLHPSYPVPPPPSPAYYRRRDSPGGMDE
PPSGWERYDGGHRGQSQKQHRHGGSGGHNKRRKETAAASSSSSDEDLSFPGEAEHGRARK
RLKSHVNSDGGSGGHAGSNQQQQQRYDELRDAIHELKRDLFAARQSSTLLSAALPSAASS
SPTTTTVCTPTGELTSGGGETPTALLSGGAKVAERAQAGVVNASCRLATASGSEAATAGP
STAGSSSCPASVVLAAAAAQAAAASQSPPKDMVDLNRRIFVAALNKLE

# Drug_Target_2_Reaction:
Cleaves -Ala!Ser- and -Ala!Ala- bonds in the scaffold protein

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
The capsid assembly protein is a component of the capsid core involved in processing and packaging of progeny DNA. Assemblin is a protease which can proteolytically cleave itself and the capsid assembly protein at the C-terminus

# Drug_Target_2_SwissProt_ID:
P16753

# Drug_Target_2_SwissProt_Name:
PPR_HCMVA

# Drug_Target_2_Synonyms:
C- terminal peptide]
Capsid assembly protein
Capsid protein P40 [Contains: Assemblin
EC 3.4.21.97
Gene UL80 protein
Gene UL80.5 protein
Protease

# Drug_Target_2_Theoretical_pI:
6.79

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Nucleus. Cytoplasm (By similarity). Note=Following virus entry, the nuclear localization signal (NLS

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
M19921

# Drug_Target_3_GenBank_ID_Protein:
328418

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
gag-pol

# Drug_Target_3_Gene_Sequence:
>3012 bp
TTTTTTAGGGAAGATCTGGCCTTCCCACAAGGGAAGGCCAGGGAATTTTCTTCAGAGCAG
ACCAGAGCCAACAGCCCCACCAGAAGAGAGCTTCAGGTTTGGGGAAGAGACAACAACTCC
CTCTCAGAAGCAGGAGCCGATAGACAAGGAACTGTATCCTTTAGCTTCCCTCAGATCACT
CTTTGGCAGCGACCCCTCGTCACAATAAAGATAGGGGGGCAATTAAAGGAAGCTCTATTA
GATACAGGAGCAGATGATACAGTATTAGAAGAAATGAATTTGCCAGGAAGATGGAAACCA
AAAATGATAGGGGGAATTGGAGGTTTTATCAAAGTAGGACAGTATGATCAGATACTCATA
GAAATCTGCGGACATAAAGCTATAGGTACAGTATTAGTAGGACCTACACCTGTCAACATA
ATTGGAAGAAATCTGTTGACTCAGATTGGCTGCACTTTAAATTTTCCCATTAGTCCTATT
GAGACTGTACCAGTAAAATTAAAGCCAGGAATGGATGGCCCAAAAGTTAAACAATGGCCA
TTGACAGAAGAAAAAATAAAAGCATTAGTAGAAATTTGTACAGAAATGGAAAAGGAAGGA
AAAATTTCAAAAATTGGGCCTGAAAATCCATACAATACTCCAGTATTTGCCATAAAGAAA
AAAGACAGTACTAAATGGAGAAAATTAGTAGATTTCAGAGAACTTAATAAGAGAACTCAA
GATTTCTGGGAAGTTCAATTAGGAATACCACATCCTGCAGGGTTAAAACAGAAAAAATCA
GTAACAGTACTGGATGTGGGCGATGCATATTTTTCAGTTCCCTTAGATAAAGACTTCAGG
AAGTATACTGCATTTACCATACCTAGTATAAACAATGAGACACCAGGGATTAGATATCAG
TACAATGTGCTTCCACAGGGATGGAAAGGATCACCAGCAATATTCCAGTGTAGCATGACA
AAAATCTTAGAGCCTTTTAGAAAACAAAATCCAGACATAGTCATCTATCAATACATGGAT
GATTTGTATGTAGGATCTGACTTAGAAATAGGGCAGCATAGAACAAAAATAGAGGAACTG
AGACAACATCTGTTGAGGTGGGGATTTACCACACCAGACAAAAAACATCAGAAAGAACCT
CCATTCCTTTGGATGGGTTATGAACTCCATCCTGATAAATGGACAGTACAGCCTATAGTG
CTGCCAGAAAAGGACAGCTGGACTGTCAATGACATACAGAAATTAGTGGGAAAATTGAAT
TGGGCAAGTCAGATTTATGCAGGGATTAAAGTAAGGCAATTATGTAAACTTCTTAGGGGA
ACCAAAGCACTAACAGAAGTAGTACCACTAACAGAAGAAGCAGAGCTAGAACTGGCAGAA
AACAGGGAGATTCTAAAAGAACCGGTACATGGAGTGTATTATGACCCATCAAAAGACTTA
ATAGCAGAAATACAGAAGCAGGGGCAAGGCCAATGGACATATCAAATTTATCAAGAGCCA
TTTAAAAATCTGAAAACAGGAAAATATGCAAGAATGAAGGGTGCCCACACTAATGATGTG
AAACAATTAACAGAGGCAGTACAAAAAATAGCCACAGAAAGCATAGTAATATGGGGAAAG
ACTCCTAAATTTAAATTACCCATACAAAAGGAAACATGGGAAGCATGGTGGACAGAGTAT
TGGCAAGCCACCTGGATTCCTGAGTGGGAGTTTGTCAATACCCCTCCCTTAGTGAAGTTA
TGGTACCAGTTAGAGAAAGAACCCATAATAGGAGCAGAAACTTTCTATGTAGATGGGGCA
GCCAATAGGGAAACTAAATTAGGAAAAGCAGGATATGTAACTGACAGAGGAAGACAAAAA
GTTGTCCCCCTAACGGACACAACAAATCAGAAGACTGAGTTACAAGCAATTCATCTAGCT
TTGCAGGATTCGGGATTAGAAGTAAACATAGTGACAGACTCACAATATGCATTGGGAATC
ATTCAAGCACAACCAGATAAGAGTGAATCAGAGTTAGTCAGTCAAATAATAGAGCAGTTA
ATAAAAAAGGAAAAAGTCTACCTGGCATGGGTACCAGCACACAAAGGAATTGGAGGAAAT
GAACAAGTAGATGGGTTGGTCAGTGCTGGAATCAGGAAAGTACTATTTTTAGATGGAATA
GATAAGGCCCAAGAAGAACATGAGAAATATCACAGTAATTGGAGAGCAATGGCTAGTGAT
TTTAACCTACCACCTGTAGTAGCAAAAGAAATAGTAGCCAGCTGTGATAAATGTCAGCTA
AAAGGGGAAGCCATGCATGGACAAGTAGACTGTAGCCCAGGAATATGGCAGCTAGATTGT
ACACATTTAGAAGGAAAAGTTATCTTGGTAGCAGTTCATGTAGCCAGTGGATATATAGAA
GCAGAAGTAATTCCAGCAGAGACAGGGCAAGAAACAGCATACTTCCTCTTAAAATTAGCA
GGAAGATGGCCAGTAAAAACAGTACATACAGACAATGGCAGCAATTTCACCAGTACTACA
GTTAAGGCCGCCTGTTGGTGGGCGGGGATCAAGCAGGAATTTGGCATTCCCTACAATCCC
CAAAGTCAAGGAGTAATAGAATCTATGAATAAAGAATTAAAGAAAATTATAGGACAGGTA
AGAGATCAGGCTGAACATCTTAAGACAGCAGTACAAATGGCAGTATTCATCCACAATTTT
AAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCA
ACAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCGGGTT
TATTACAGGGACAGCAGAGATCCAGTTTGGAAAGGACCAGCAAAGCTCCTCTGGAAAGGT
GAAGGGGCAGTAGTAATACAAGATAATAGTGACATAAAAGTAGTGCCAAGAAGAAAAGCA
AAGATCATCAGGGATTATGGAAAACAGATGGCAGGTGATGATTGTGTGGCAAGTAGACAG
GATGAGGATTAA

# Drug_Target_3_General_Function:
Involved in RNA binding

# Drug_Target_3_General_References:
2200122	Erickson J, Neidhart DJ, VanDrie J, Kempf DJ, Wang XC, Norbeck DW, Plattner JJ, Rittenhouse JW, Turon M, Wideburg N, et al.: Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science. 1990 Aug 3;249(4968):527-33.
2201682	Fitzgerald PM, McKeever BM, VanMiddlesworth JF, Springer JP, Heimbach JC, Leu CT, Herber WK, Dixon RA, Darke PL: Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution. J Biol Chem. 1990 Aug 25;265(24):14209-19.
2548279	Wlodawer A, Miller M, Jaskolski M, Sathyanarayana BK, Baldwin E, Weber IT, Selk LM, Clawson L, Schneider J, Kent SB: Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science. 1989 Aug 11;245(4918):616-21.
7929352	Chen Z, Li Y, Chen E, Hall DL, Darke PL, Culberson C, Shafer JA, Kuo LC: Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. J Biol Chem. 1994 Oct 21;269(42):26344-8.
7966331	Massiah MA, Starich MR, Paschall C, Summers MF, Christensen AM, Sundquist WI: Three-dimensional structure of the human immunodeficiency virus type 1 matrix protein. J Mol Biol. 1994 Nov 25;244(2):198-223.
8610175	Hill CP, Worthylake D, Bancroft DP, Christensen AM, Sundquist WI: Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3099-104.
8623533	Welker R, Kottler H, Kalbitzer HR, Krausslich HG: Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase. Virology. 1996 May 1;219(1):228-36.
8977101	Bujacz G, Alexandratos J, Qing ZL, Clement-Mella C, Wlodawer A: The catalytic domain of human immunodeficiency virus integrase: ordered active site in the F185H mutant. FEBS Lett. 1996 Dec 2;398(2-3):175-8.
8980234	Gamble TR, Vajdos FF, Yoo S, Worthylake DK, Houseweart M, Sundquist WI, Hill CP: Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell. 1996 Dec 27;87(7):1285-94.
9228950	Cai M, Zheng R, Caffrey M, Craigie R, Clore GM, Gronenborn AM: Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat Struct Biol. 1997 Jul;4(7):567-77.
9346481	Gamble TR, Yoo S, Vajdos FF, von Schwedler UK, Worthylake DK, Wang H, McCutcheon JP, Sundquist WI, Hill CP: Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein. Science. 1997 Oct 31;278(5339):849-53.
9689049	Goldgur Y, Dyda F, Hickman AB, Jenkins TM, Craigie R, Davies DR: Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9150-4.
9878383	Turner BG, Summers MF: Structural biology of HIV. J Mol Biol. 1999 Jan 8;285(1):1-32.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
2237

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
161691

# Drug_Target_3_Name:
Gag-Pol polyprotein

# Drug_Target_3_Number_of_Residues:
1435

# Drug_Target_3_PDB_ID:
1VRU

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00075	RnaseH
PF00077	RVP
PF00078	RVT_1
PF00098	zf-CCHC
PF00540	Gag_p17
PF00552	Integrase
PF00607	Gag_p24
PF00665	rve
PF02022	Integrase_Zn
PF06815	RVT_connect
PF06817	RVT_thumb

# Drug_Target_3_Protein_Sequence:
>Gag-Pol polyprotein
MGARASVLSGGELDKWEKIRLRPGGKKQYKLKHIVWASRELERFAVNPGLLETSEGCRQI
LGQLQPSLQTGSEELRSLYNTIAVLYCVHQRIDVKDTKEALDKIEEEQNKSKKKAQQAAA
DTGNNSQVSQNYPIVQNLQGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGAT
PQDLNTMLNTVGGHQAAMQMLKETINEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTT
STLQEQIGWMTHNPPIPVGEIYKRWIILGLNKIVRMYSPTSILDIRQGPKEPFRDYVDRF
YKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPGATLEEMMTACQGVGGPGHKA
RVLAEAMSQVTNPATIMIQKGNFRNQRKTVKCFNCGKEGHIAKNCRAPRKKGCWKCGKEG
HQMKDCTERQANFLREDLAFPQGKAREFSSEQTRANSPTRRELQVWGRDNNSLSEAGADR
QGTVSFSFPQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGG
FIKVGQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLK
PGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRK
LVDFRELNKRTQDFWEVQLGIPHPAGLKQKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIP
SINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVIYQYMDDLYVGSDL
EIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWT
VNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKALTEVVPLTEEAELELAENREILKEP
VHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMKGAHTNDVKQLTEAVQ
KIATESIVIWGKTPKFKLPIQKETWEAWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEP
IIGAETFYVDGAANRETKLGKAGYVTDRGRQKVVPLTDTTNQKTELQAIHLALQDSGLEV
NIVTDSQYALGIIQAQPDKSESELVSQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDGLVS
AGIRKVLFLDGIDKAQEEHEKYHSNWRAMASDFNLPPVVAKEIVASCDKCQLKGEAMHGQ
VDCSPGIWQLDCTHLEGKVILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTV
HTDNGSNFTSTTVKAACWWAGIKQEFGIPYNPQSQGVIESMNKELKKIIGQVRDQAEHLK
TAVQMAVFIHNFKRKGGIGGYSAGERIVDIIATDIQTKELQKQITKIQNFRVYYRDSRDP
VWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQDED

# Drug_Target_3_Reaction:
deoxynucleoside triphosphate + DNAn = diphosphate + DNAn+1

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Integrase performs the integration of the newly synthesized dsDNA copy of the viral genome into the host chromosome. The integrated DNA is called provirus

# Drug_Target_3_SwissProt_ID:
P12497

# Drug_Target_3_SwissProt_Name:
POL_HV1N5

# Drug_Target_3_Synonyms:
Pr160Gag-Pol

# Drug_Target_3_Theoretical_pI:
8.83

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
NOS3

# Drug_Target_4_GenBank_ID_Gene:
M93718

# Drug_Target_4_GenBank_ID_Protein:
189212

# Drug_Target_4_GeneCard_ID:
NOS3

# Drug_Target_4_Gene_Name:
NOS3

# Drug_Target_4_Gene_Sequence:
>3612 bp
ATGGGCAACTTGAAGAGCGTGGCCCAGGAGCCTGGGCCACCCTGCGGCCTGGGGCTGGGG
CTGGGCCTTGGGCTGTGCGGCAAGCAGGGCCCAGCCACCCCGGCCCCTGAGCCCAGCCGG
GCCCCAGCATCCCTACTCCCACCAGCGCCAGAACACAGCCCCCCGAGCTCCCCGCTAACC
CAGCCCCCAGAGGGGCCCAAGTTCCCTCGTGTGAAGAACTGGGAGGTGGGGAGCATCACC
TATGACACCCTCAGCGCCCAGGCGCAGCAGGATGGGCCCTGCACCCCAAGACGCTGCCTG
GGCTCCCTGGTATTTCCACGGAAACTACAGGGCCGGCCCTCCCCCGGCCCCCCGGCCCCT
GAGCAGCTGCTGAGTCAGGCCCGGGACTTCATCAACCAGTACTACAGCTCCATTAAGAGG
AGCGGCTCCCAGGCCCACGAACAGCGGCTTCAAGAGGTGGAAGCCGAGGTGGCAGCCACA
GGCACCTACCAGCTTAGGGAGAGCGAGCTGGTGTTCGGGGCTAAGCAGGCCTGGCGCAAC
GCTCCCCGCTGCGTGGGCCGGATCCAGTGGGGGAAGCTGCAGGTGTTCGATGCCCGGGAC
TGCAGGTCTGCACAGGAAATGTTCACCTACATCTGCAACCACATCAAGTATGCCACCAAC
CGGGGCAACCTTCGCTCGGCCATCACAGTGTTCCCGCAGCGCTGCCCTGGCCGAGGAGAC
TTCCGAATCTGGAACAGCCAGCTGGTGCGCTACGCGGGCTACCGGCAGCAGGACGGCTCT
GTGCGGGGGGACCCAGCCAACGTGGAGATCACCGAGCTCTGCATTCAGCACGGCTGGACC
CCAGGAAACGGTCGCTTCGACGTGCTGCCCCTGCTGCTGCAGGCCCCAGATGAGCCCCCA
GAACTCTTCCTTCTGCCCCCCGAGCTGGTCCTTGAGGTGCCCCTGGAGCACCCCACGCTG
GAGTGGTTTGCAGCCCTGGGCCTGCGCTGGTACGCCCTCCCGGCAGTGTCCAACATGCTG
CTGGAAATTGGGGGCCTGGAGTTCCCCGCAGCCCCCTTCAGTGGCTGGTACATGAGCACT
GAGATCGGCACGAGGAACCTGTGTGACCCTCACCGCTACAACATCCTGGAGGATGTGGCT
GTCTGCATGGACCTGGATACCCGGACCACCTCGTCCCTGTGGAAAGACAAGGCAGCAGTG
GAAATCAACGTGGCCGTGCTGCACAGTTACCAGCTAGCCAAAGTCACCATCGTGGACCAC
CACGCCGCCACGGCCTCTTTCATGAAGCACCTGGAGAATGAGCAGAAGGCCAGGGGGGGC
TGCCCTGCAGACTGGGCCTGGATCGTGCCCCCCATCTCGGGCAGCCTCACTCCTGTTTTC
CATCAGGAGATGGTCAACTATTTCCTGTCCCCGGCCTTCCGCTACCAGCCAGACCCCTGG
AAGGGGAGTGCCGCCAAGGGCACCGGCATCACCAGGAAGAAGACCTTTAAAGAAGTGGCC
AACGCCGTGAAGATCTCCGCCTCGCTCATGGGCACGGTGATGGCGAAGCGAGTGAAGGCG
ACAATCCTGTATGGCTCCGAGACCGGCCGGGCCCAGAGCTACGCACAGCAGCTGGGGAGA
CTCTTCCGGAAGGCTTTTGATCCCCGGGTCCTGTGTATGGATGAGTATGACGTGGTGTCC
CTCGAACACGAGACGCTGGTGCTGGTGGTAACCAGCACATTTGGGAATGGGGATCCCCCG
GAGAATGGAGAGAGCTTTGCAGCTGCCCTGATGGAGATGTCCGGCCCCTACAACAGCTCC
CCTCGGCCGGAACAGCACAAGAGTTATAAGATCCGCTTCAACAGCATCTCCTGCTCAGAC
CCACTGGTGTCCTCTTGGCGGCGGAAGAGGAAGGAGTCCAGTAACACAGACAGTGCAGGG
GCCCTGGGCACCCTCAGGTTCTGTGTGTTCGGGCTCGGCTCCCGGGCATACCCCCACTTC
TGCGCCTTTGCTCGTGCCGTGGACACACGGCTGGAGGAACTGGGCGGGGAGCGGCTGCTG
CAGCTGGGCCAGGGCGACGAGCTGTGCGGCCAGGAGGAGGCCTTCCGAGGCTGGGCCCAG
GCTGCCTTCCAGGCCGCCTGTGAGACCTTCTGTGTGGGAGAGGATGCCAAGGCCGCCGCC
CGAGACATCTTCAGCCCCAAACGGAGCTGGAAGCGCCAGAGGTACCGGCTGAGCGCCCAG
GCCGAGGGCCTGCAGTTGCTGCCAGGTCTGATCCACGTGCACAGGCGGAAGATGTTCCAG
GCTACAATCCGCTCAGTGGAAAACCTGCAAAGCAGCAAGTCCACGAGGGCCACCATCCTG
GTGCGCCTGGACACCGGAGGCCAGGAGGGGCTGCAGTACCAGCCGGGGGACCACATAGGT
GTCTGCCCGCCCAACCGGCCCGGCCTTGTGGAGGCGCTGCTGAGCCGCGTGGAGGACCCG
CCGGCGCCCACTGAGCCCGTGGCAGTAGAGCAGCTGGAGAAGGGCAGCCCTGGTGGCCCT
CCCCCCGGCTGGGTGCGGGACCCCCGGCTGCCCCCGTGCACGCTGCGCCAGGCTCTCACC
TTCTTCCTGGACATCACCTCCCCACCCAGCCCTCAGCTCTTGCGGCTGCTCAGCACCTTG
GCAGAAGAGCCCAGGGAACAGCAGGAGCTGGAGGCCCTCAGCCAGGATCCCCGACGCTAC
GAGGAGTGGAAGTGGTTCCGCTGCCCCACGCTGCTGGAGGTGCTGGAGCAGTTCCCGTCG
GTGGCGCTGCCTGCCCCACTGCTCCTCACCCAGCTGCCTCTGCTCCAGCCCCGGTACTAC
TCAGTCAGCTCGGCACCCAGCACCCACCCAGGAGAGATCCACCTCACTGTAGCTGTGCTG
GCATACAGGACTCAGGATGGGCTGGGCCCCCTGCACTATGGAGTCTGCTCCACGTGGCTA
AGCCAGCTCAAGCCCGGAGACCCTGTGCCCTGCTTCATCCGGGGGGCTCCCTCCTTCCGG
CTGCCACCCGATCCCAGCTTGCCCTGCATCCTGGTGGGTCCAGGCACTGGCATTGCCCCC
TTCCGGGGATTCTGGCAGGAGCGGCTGCATGACATTGAGAGCAAAGGGCTGCAGCCCACT
CCCATGACTTTGGTGTTCGGCTGCCGATGCTCCCAACTTGACCATCTCTACCGCGACGAG
GTGCAGAACGCCCAGCAGCGCGGGGTGTTTGGCCGAGTCCTCACCGCCTTCTCCCGGGAA
CCTGACAACCCCAAGACCTACGTGCAGGACATCCTGAGGACGGAGCTGGCTGCGGAGGTG
CACCGCGTGCTGTGCCTCGAGCGGGGCCACATGTTTGTCTGCGGCGATGTTACCATGGCA
ACCAACGTCCTGCAGACCGTGCAGCGCATCCTGGCGACGGAGGGCGACATGGAGCTGGAC
GAGGCCGGCGACGTCATCGGCGTGCTGCGGGATCAGCAACGCTACCACGAAGACATTTTC
GGGCTCACGCTGCGCACCCAGGAGGTGACAAGCCGCATACGCACCCAGAGCTTTTCCTTG
CAGGAGCGTCAGTTGCGGGGCGCAGTGCCCTGGGCGTTCGACCCTCCCGGCTCAGACACC
AACAGCCCCTGA

# Drug_Target_4_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_4_General_References:
10074942	Fischmann TO, Hruza A, Niu XD, Fossetta JD, Lunn CA, Dolphin E, Prongay AJ, Reichert P, Lundell DJ, Narula SK, Weber PC: Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. Nat Struct Biol. 1999 Mar;6(3):233-42.
12437348	Rosenfeld RJ, Garcin ED, Panda K, Andersson G, Aberg A, Wallace AV, Morris GM, Olson AJ, Stuehr DJ, Tainer JA, Getzoff ED: Conformational changes in nitric oxide synthases induced by chlorzoxazone and nitroindazoles: crystallographic and computational analyses of inhibitor potency. Biochemistry. 2002 Nov 26;41(47):13915-25.
1378832	Janssens SP, Shimouchi A, Quertermous T, Bloch DB, Bloch KD: Cloning and expression of a cDNA encoding human endothelium-derived relaxing factor/nitric oxide synthase. J Biol Chem. 1992 Jul 25;267(21):14519-22.
1379542	Marsden PA, Schappert KT, Chen HS, Flowers M, Sundell CL, Wilcox JN, Lamas S, Michel T: Molecular cloning and characterization of human endothelial nitric oxide synthase. FEBS Lett. 1992 Aug 3;307(3):287-93.
7475956	Sase K, Michel T: Expression of constitutive endothelial nitric oxide synthase in human blood platelets. Life Sci. 1995;57(22):2049-55.
7509596	Nadaud S, Bonnardeaux A, Lathrop M, Soubrier F: Gene structure, polymorphism and mapping of the human endothelial nitric oxide synthase gene. Biochem Biophys Res Commun. 1994 Feb 15;198(3):1027-33.
7514568	Robinson LJ, Weremowicz S, Morton CC, Michel T: Isolation and chromosomal localization of the human endothelial nitric oxide synthase (NOS3) gene. Genomics. 1994 Jan 15;19(2):350-7.
7519987	Miyahara K, Kawamoto T, Sase K, Yui Y, Toda K, Yang LX, Hattori R, Aoyama T, Yamamoto Y, Doi Y, et al.: Cloning and structural characterization of the human endothelial nitric-oxide-synthase gene. Eur J Biochem. 1994 Aug 1;223(3):719-26.
7688726	Marsden PA, Heng HH, Scherer SW, Stewart RJ, Hall AV, Shi XM, Tsui LC, Schappert KT: Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem. 1993 Aug 15;268(23):17478-88.
9737779	Yoshimura M, Yasue H, Nakayama M, Shimasaki Y, Sumida H, Sugiyama S, Kugiyama K, Ogawa H, Ogawa Y, Saito Y, Miyamoto Y, Nakao K: A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet. 1998 Jul;103(1):65-9.

# Drug_Target_4_HGNC_ID:
HGNC:7876

# Drug_Target_4_HPRD_ID:
01224

# Drug_Target_4_ID:
291

# Drug_Target_4_Locus:
7q36

# Drug_Target_4_Molecular_Weight:
133159

# Drug_Target_4_Name:
Nitric-oxide synthase, endothelial

# Drug_Target_4_Number_of_Residues:
1202

# Drug_Target_4_PDB_ID:
3NOS

# Drug_Target_4_Pathway:
Bevacizumab Pathway	SMP00420
Vatalanib Pathway	SMP00421

# Drug_Target_4_Pfam_Domain_Function:
PF00175	NAD_binding_1
PF00258	Flavodoxin_1
PF00667	FAD_binding_1
PF02898	NO_synthase

# Drug_Target_4_Protein_Sequence:
>Nitric-oxide synthase, endothelial
GNLKSVAQEPGPPCGLGLGLGLGLCGKQGPATPAPEPSRAPASLLPPAPEHSPPSSPLTQ
PPEGPKFPRVKNWEVGSITYDTLSAQAQQDGPCTPRRCLGSLVFPRKLQGRPSPGPPAPE
QLLSQARDFINQYYSSIKRSGSQAHEQRLQEVEAEVAATGTYQLRESELVFGAKQAWRNA
PRCVGRIQWGKLQVFDARDCRSAQEMFTYICNHIKYATNRGNLRSAITVFPQRCPGRGDF
RIWNSQLVRYAGYRQQDGSVRGDPANVEITELCIQHGWTPGNGRFDVLPLLLQAPDEPPE
LFLLPPELVLEVPLEHPTLEWFAALGLRWYALPAVSNMLLEIGGLEFPAAPFSGWYMSTE
IGTRNLCDPHRYNILEDVAVCMDLDTRTTSSLWKDKAAVEINVAVLHSYQLAKVTIVDHH
AATASFMKHLENEQKARGGCPADWAWIVPPISGSLTPVFHQEMVNYFLSPAFRYQPDPWK
GSAAKGTGITRKKTFKEVANAVKISASLMGTVMAKRVKATILYGSETGRAQSYAQQLGRL
FRKAFDPRVLCMDEYDVVSLEHETLVLVVTSTFGNGDPPENGESFAAALMEMSGPYNSSP
RPEQHKSYKIRFNSISCSDPLVSSWRRKRKESSNTDSAGALGTLRFCVFGLGSRAYPHFC
AFARAVDTRLEELGGERLLQLGQGDELCGQEEAFRGWAQAAFQAACETFCVGEDAKAAAR
DIFSPKRSWKRQRYRLSAQAEGLQLLPGLIHVHRRKMFQATIRSVENLQSSKSTRATILV
RLDTGGQEGLQYQPGDHIGVCPPNRPGLVEALLSRVEDPPAPTEPVAVEQLEKGSPGGPP
PGWVRDPRLPPCTLRQALTFFLDITSPPSPQLLRLLSTLAEEPREQQELEALSQDPRRYE
EWKWFRCPTLLEVLEQFPSVALPAPLLLTQLPLLQPRYYSVSSAPSTHPGEIHLTVAVLA
YRTQDGLGPLHYGVCSTWLSQLKPGDPVPCFIRGAPSFRLPPDPSLPCILVGPGTGIAPF
RGFWQERLHDIESKGLQPTPMTLVFGCRCSQLDHLYRDEVQNAQQRGVFGRVLTAFSREP
DNPKTYVQDILRTELAAEVHRVLCLERGHMFVCGDVTMATNVLQTVQRILATEGDMELDE
AGDVIGVLRDQQRYHEDIFGLTLRTQEVTSRIRTQSFSLQERQLRGAVPWAFDPPGSDTN
SP

# Drug_Target_4_Reaction:
L-arginine + n NADPH + n H+ + m O2 = citrulline + nitric oxide + n NADP+

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. No mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets

# Drug_Target_4_SwissProt_ID:
P29474

# Drug_Target_4_SwissProt_Name:
NOS3_HUMAN

# Drug_Target_4_Synonyms:
Constitutive NOS
EC 1.14.13.39
EC-NOS
Endothelial NOS
NOS type III
NOSIII
cNOS
eNOS

# Drug_Target_4_Theoretical_pI:
7.27

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Cytoplasm. Golgi apparatus
Golgi apparatus membrane
cytoplasmic side
peripheral membrane protein

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
COPG

# Drug_Target_5_GenBank_ID_Gene:
AF100756

# Drug_Target_5_GenBank_ID_Protein:
5410298

# Drug_Target_5_GeneCard_ID:
COPG

# Drug_Target_5_Gene_Name:
COPG

# Drug_Target_5_Gene_Sequence:
>2625 bp
ATGTTGAAGAAATTCGACAAGAAGGATGAGGAGTCAGGTGGAGGCTCCAACCCATTCCAG
CACCTTGAGAAGAGTGCGGTACTCCAGGAGGCCCGTGTATTTAATGAAACTCCCATCAAC
CCTCGGAAATGTGCCCACATCCTCACCAAGATTCTTTATCTCATAAACCAGGGGGAGCAC
CTGGGGACCACGGAAGCGACCGAGGCCTTCTTTGCCATGACCAAGCTCTTTCAGTCCAAT
GACCCCACACTCCGTCGGATGTGCTACTTGACCATCAAGGAGATGTCTTGCATTGCAGAG
GATGTCATCATTGTCACCAGCAGCCTAACAAAAGACATGACTGGGAAAGAAGACAACTAC
CGGGGCCCGGCCGTGCGAGCCCTCTGCCAGATCACTGATAGCACCATGCTGCAGGCTATT
GAGCGCTACATGAAACAAGCCATTGTGGACAAGGTGCCCAGTGTCTCCAGCTCTGCCCTC
GTGTCTTCCTTGCACCTGCTGAAGTGCAGCTTTGACGTGGTCAAGCGCTGGGTGAATGAG
GCTCAGGAGGCAGCATCCAGTGATAACATCATGGTCCAGTACCACGCACTAGGGCTCCTG
TACCATGTGCGTAAGAATGACCGCCTAGCCGTCAATAAGATGATCAGCAAGGTCACACGG
CATGGCCTTAAGTCTCCCTTTGCCTACTGCATGATGATCCGGGTGGCCAGCAAGCAGCTG
GAAGAGGAGGATGGCAGCCGTGACAGCCCACTGTTTGACTTCATCGAGAGCTGCTTGCGC
AACAAGCACGAGATGGTGGTGTATGAAGCCGCCTCGGCCATTGTCAACCTGCCTGGGTGC
AGCGCCAAGGAGCTGGCCCCAGCTGTCTCAGTGCTCCAGCTCTTCTGCAGCTCCCCCAAG
GCCGCCCTCCGTTACGCCGCCGTCCGCACCCTCAACAAGGTGGCCATGAAGCACCCGTCC
GCTGTGACAGCTTGTAATCTGGATCTGGAGAACCTGGTCACAGATTCAAACCGCAGCATT
GCCACGCTGGCCATCACCACCCTCCTTAAGACGGGCAGCGAGAGCAGCATCGACCGCCTC
ATGAAGCAGATCTCCTCCTTCATGTCAGAAATCTCGGATGAATTCAAGGTGGTGGTTGTC
CAGGCCATCAGTGCCCTGTGTCAGAAATATCCTCGCAAACACGCCGTCCTTATGAACTTC
CTGTTCACCATGCTGCGGGAAGAGGGTGGCTTTGAGTATAAGCGCGCTATCGTGGACTGC
ATCATCAGCATCATTGAAGAGAACTCAGAGAGCAAGGAGACAGGGCTGTCACATCTGTGC
GAGTTCATCGAGGACTGCGAGTTCACAGTGCTGGCCACCCGTATTCTACATCTCCTGGGC
CAGGAGGGGCCCAAGACCACCAATCCCTCAAAGTACATCCGCTTCATCTATAACCGAGTG
GTCTTGGAGCATGAGGAGGTCCGGGCAGGTGCTGTGAGTGCTCTGGCGAAGTTTGGAGCC
CAGAATGAAGAGATGTTACCCAGTATCTTGGTGTTGCTGAAGAGGTGTGTGATGGATGAT
GACAATGAAGTAAGGGACCGAGCCACCTTCTACCTAAATGTCCTGGAGCAGAAGCAGAAG
GCCCTTAATGCAGGCTATATCCTAAATGGTCTGACTGTGTCCATCCCTGGTCTGGAGAGG
GCTCTGCAGCAGTACACTCTAGAACCATCAGAAAAACCTTTTGACCTCAAGTCTGTGCCC
CTGGCCACGGCGCCCATGGCAGAGCAGAGAACAGAAAGTACCCCCATCACAGCAGTCAAA
CAGCCTGAGAAAGTGGCAGCTACCAGGCAGGAGATCTTCCAGGAGCAGTTGGCAGCAGTG
CCAGAGTTCCGCGGTCTTGGGCCCCTCTTCAAGTCCTCGCCTGAGCCCGTGGCCCTCACC
GAGTCAGAGACGGAGTATGTCATCCGCTGCACCAAACACACCTTCACCAACCACATGGTT
TTTCAGTTTGACTGCACAAACACACTCAATGACCAGACCTTGGAGAATGTCACAGTGCAG
ATGGAGCCCACTGAGGCCTATGAGGTGCTCTGTTACGTGCCTGCCCGGAGCCTGCCCTAC
AACCAGCCCGGGACCTGCTACACACTGGTGGCACTGCCCAAAGAAGACCCCACAGCTGTG
GCCTGCACATTCAGCTGCATGATGAAGTTCACTGTCAAGGACTGTGATCCCACCACTGGG
GAGACTGATGACGAAGGCTATGAGGATGAGTATGTGCTGGAAGATCTGGAAGTTACTGTA
GCTGATCACATTCAAAAGGTCATGAAACTGAACTTCGAAGCAGCCTGGGATGAGGTAGGG
GATGAATTTGAGAAGGAGGAAACGTTCACCTTGTCTACCATCAAGACACTTGAAGAGGCT
GTGGGTAATATTGTGAAGTTCTTGGGAATGCACCCTTGTGAGAGGTCAGACAAAGTGCCG
GATAACAAGAACACCCACACGTTGCTCCTGGCTGGTGTGTTCCGGGGTGGTCATGACATC
CTGGTGCGCTCCCGGCTGCTGCTTTTGGACACAGTGACAATGCAGGTGACAGCCAGAAGT
TTGGAGGAGCTGCCAGTAGACATCATCTTGGCATCTGTGGGATAA

# Drug_Target_5_General_Function:
Involved in protein binding and clathrin coated vesicle binding

# Drug_Target_5_General_References:
10931946	Hu RM, Han ZG, Song HD, Peng YD, Huang QH, Ren SX, Gu YJ, Huang CH, Li YB, Jiang CL, Fu G, Zhang QH, Gu BW, Dai M, Mao YF, Gao GF, Rong R, Ye M, Zhou J, Xu SH, Gu J, Shi JX, Jin WR, Zhang CK, Wu TM, Huang GY, Chen Z, Chen MD, Chen JL: Gene expression profiling in the human hypothalamus-pituitary-adrenal axis and full-length cDNA cloning. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9543-8.

# Drug_Target_5_HGNC_ID:
HGNC:2236

# Drug_Target_5_HPRD_ID:
09887

# Drug_Target_5_ID:
2906

# Drug_Target_5_Locus:
3q21.3

# Drug_Target_5_Molecular_Weight:
97719

# Drug_Target_5_Name:
Coatomer subunit gamma

# Drug_Target_5_Number_of_Residues:
874

# Drug_Target_5_PDB_ID:
1PZD

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF01602	Adaptin_N
PF08752	Gamma-COP

# Drug_Target_5_Protein_Sequence:
>Coatomer subunit gamma
MLKKFDKKDEESGGGSNPFQHLEKSAVLQEARVFNETPINPRKCAHILTKILYLINQGEH
LGTTEATEAFFAMTKLFQSNDPTLRRMCYLTIKEMSCIAEDVIIVTSSLTKDMTGKEDNY
RGPAVRALCQITDSTMLQAIERYMKQAIVDKVPSVSSSALVSSLHLLKCSFDVVKRWVNE
AQEAASSDNIMVQYHALGLLYHVRKNDRLAVNKMISKVTRHGLKSPFAYCMMIRVASKQL
EEEDGSRDSPLFDFIESCLRNKHEMVVYEAASAIVNLPGCSAKELAPAVSVLQLFCSSPK
AALRYAAVRTLNKVAMKHPSAVTACNLDLENLVTDSNRSIATLAITTLLKTGSESSIDRL
MKQISSFMSEISDEFKVVVVQAISALCQKYPRKHAVLMNFLFTMLREEGGFEYKRAIVDC
IISIIEENSESKETGLSHLCEFIEDCEFTVLATRILHLLGQEGPKTTNPSKYIRFIYNRV
VLEHEEVRAGAVSALAKFGAQNEEMLPSILVLLKRCVMDDDNEVRDRATFYLNVLEQKQK
ALNAGYILNGLTVSIPGLERALQQYTLEPSEKPFDLKSVPLATAPMAEQRTESTPITAVK
QPEKVAATRQEIFQEQLAAVPEFRGLGPLFKSSPEPVALTESETEYVIRCTKHTFTNHMV
FQFDCTNTLNDQTLENVTVQMEPTEAYEVLCYVPARSLPYNQPGTCYTLVALPKEDPTAV
ACTFSCMMKFTVKDCDPTTGETDDEGYEDEYVLEDLEVTVADHIQKVMKLNFEAAWDEVG
DEFEKEETFTLSTIKTLEEAVGNIVKFLGMHPCERSDKVPDNKNTHTLLLAGVFRGGHDI
LVRSRLLLLDTVTMQVTARSLEELPVDIILASVG

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
The coatomer is a cytosolic protein complex that binds to dilysine motifs and reversibly associates with Golgi non- clathrin-coated vesicles, which further mediate biosynthetic protein transport from the ER, via the Golgi up to the trans Golgi network. Coatomer complex is required for budding from Golgi membranes, and is essential for the retrograde Golgi-to-ER transport of dilysine-tagged proteins. In mammals, the coatomer can only be recruited by membranes associated to ADP-ribosylation factors (ARFs), which are small GTP-binding proteins; the complex also influences the Golgi structural integrity, as well as the processing, activity, and endocytic recycling of LDL receptors

# Drug_Target_5_SwissProt_ID:
Q9Y678

# Drug_Target_5_SwissProt_Name:
COPG_HUMAN

# Drug_Target_5_Synonyms:
Gamma-COP
Gamma-coat protein

# Drug_Target_5_Theoretical_pI:
5.14

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Cytoplasmic

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
V01149

# Drug_Target_6_GenBank_ID_Protein:
61253

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
Not Available

# Drug_Target_6_Gene_Sequence:
>6630 bp
ATGGGTGCTCAGGTTTCATCACAGAAAGTGGGCGCACATGAAAACTCAAATAGAGCGTAT
GGTGGTTCTACCATTAATTACACCACCATTAATTATTATAGAGATTCAGCTAGTAACGCG
GCTTCGAAACAGGACTTCTCTCAAGACCCTTCCAAGTTCACCGAGCCCATCAAGGATGTC
CTGATAAAAACAGCCCCAATGCTAAACTCGCCAAACATAGAGGCTTGCGGGTATAGCGAT
AGAGTACTGCAATTAACACTGGGAAACTCCACTATAACCACACAGGAGGCGGCTAATTCA
GTAGTCGCTTATGGGCGTTGGCCTGAATATCTGAGGGACAGCGAAGCCAATCCAGTGGAC
CAGCCGACAGAACCAGACGTCGCTGCATGCAGGTTTTATACGCTAGACACCGTGTCTTGG
ACGAAAGAGTCGCGAGGGTGGTGGTGGAAGTTGCCTGATGCACTGAGGGACATGGGACTC
TTTGGGCAAAATATGTACTACCACTACCTAGGTAGGTCCGGGTACACCGTGCATGTACAG
TGTAACGCCTCCAAATTCCACCAGGGGGCACTAGGGGTATTCGCCGTACCAGAGATGTGT
CTGGCCGGGGATAGCAACACCACTACCATGCACACCAGCTATCAAAATGCCAATCCTGGC
GAGAAAGGAGGCACTTTCACGGGTACGTTCACTCCTGACAACAACCAGACATCACCTGCC
CGCAGGTTCTGCCCGGTGGATTACCTCCTTGGAAATGGCACGTTGTTGGGGAATGCCTTT
GTGTTCCCGCACCAGATAATAAACCTACGGACCAACAACTGTGCTACACTGGTACTCCCT
TACGTGAACTCCCTCTCGATAGATAGTATGGTAAAGCACAATAATTGGGGAATTGCAATA
TTACCATTGGCCCCATTAAATTTTGCTAGTGAGTCCTCCCCAGAGATTCCAATCACCTTG
ACCATAGCCCCTATGTGCTGTGAGTTCAATGGATTAAGAAACATCACCCTGCCACGCTTA
CAGGGCCTGCCGGTCATGAACACCCCTGGTAGCAATCAATATCTTACTGCAGACAACTTC
CAGTCACCGTGTGCGCTGCCTGAATTTGATGTGACCCCACCTATTGACATACCCGGTGAA
GTAAAGAACATGATGGAATTGGCAGAAATCGACACCATGATTCCCTTTGACTTAAGTGCC
ACAAAAAAGAACACCATGGAAATGTATAGGGTTCGGTTAAGTGACAAACCACATACAGAC
GATCCCATACTCTGCCTGTCACTCTCTCCAGCTTCAGATCCTAGGTTGTCACATACTATG
CTTGGAGAAATCCTAAATTACTACACACACTGGGCAGGATCCCTGAAGTTCACGTTTCTG
TTCTGTGGATTCATGATGGCAACTGGCAAACTGTTGGTGTCATACGCGCCTCCTGGAGCC
GACCCACCAAAGAAGCGTAAGGAGGCGATGTTGGGAACACATGTGATCTGGGACATAGGA
CTGCAGTCCTCATGTACTATGGTAGTGCCATGGATTAGCAACACCACGTATCGGCAAACC
ATAGATGATAGTTTCACCGAAGGCGGATACATCAGCGTCTTCTACCAAACTAGAATAGTC
GTCCCTCTTTCGACACCCAGAGAGATGGACATCCTTGGTTTTGTGTCAGCGTGTAATGAC
TTCAGCGTGCGCTTGTTGCGAGATACCACACATATAGAGCAAAAAGCGCTAGCACAGGGG
TTAGGTCAGATGCTTGAAAGCATGATTGACAACACAGTCCGTGAAACGGTGGGGGCGGCA
ACATCTAGAGACGCTCTCCCAAACACTGAAGCCAGTGGACCAACACACTCCAAGGAAATT
CCGGCACTCACCGCAGTGGAAACTGGGGCCACAAATCCACTAGTCCCTTCTGATACAGTG
CAAACCAGACATGTTGTACAACATAGGTCAAGGTCAGAGTCTAGCATAGAGTCTTTCTTC
GCGCGGGGTGCATGCGTGACCATTATGACCGTGGATAACCCAGCTTCCACCACGAATAAG
GATAAGCTATTTGCAGTGTGGAAGATCACTTATAAAGATACTGTCCAGTTACGGAGGAAA
TTGGAGTTCTTCACCTATTCTAGATTTGATATGGAACTTACCTTTGTGGTTACTGCAAAT
TTCACTGAGACTAACAATGGGCATGCCTTAAATCAAGTGTACCAAATTATGTACGTACCA
CCAGGCGCTCCAGTGCCCGAGAAATGGGACGACTACACATGGCAAACCTCATCAAATCCA
TCAATCTTTTACACCTACGGAACAGCTCCAGCCCGGATCTCGGTACCGTATGTTGGTATT
TCGAACGCCTATTCACACTTTTACGACGGTTTTTCCAAAGTACCACTGAAGGACCAGTCG
GCAGCACTAGGTGACTCCCTTTATGGTGCAGCATCTCTAAATGACTTCGGTATTTTGGCT
GTTAGAGTAGTCAATGATCACAACCCGACCAAGGTCACCTCCAAAATCAGAGTGTATCTA
AAACCCAAACACATCAGAGTCTGGTGCCCGCGTCCACCGAGGGCAGTGGCGTACTACGGC
CCTGGAGTGGATTACAAGGATGGTACGCTTACACCCCTCTCCACCAAGGATCTGACCACA
TATGGATTCGGACACCAAAACAAAGCGGTGTACACTGCAGGTTACAAAATTTGCAACTAC
CACTTGGCCACTCAGGATGATTTGCAAAACGCAGTGAACGTCATGTGGAGTAGAGACCTC
TTAGTCACAGAATCAAGAGCCCAGGGCACCGATTCAATCGCAAGGTGCAATTGCAACGCA
GGGGTGTACTACTGCGAGTCTAGAAGGAAATACTACCCAGTATCCTTCGTTGGCCCAACG
TTCCAGTACATGGAGGCTAATAACTATTACCCAGCTAGGTACCAGTCCCATATGCTCATT
GGCCATGGATTCGCATCTCCAGGGGATTGTGGTGGCATACTCAGATGTCACCACGGGGTG
ATAGGGATCATTACTGCTGGTGGCGAAGGGTTGGTTGCATTTTCAGACATTAGAGACTTG
TATGCCTACGAAGAAGAAGCCATGGAACAAGGCATCACCAATTACATAGAGTCACTTGGG
GCCGCATTTGGAAGTGGATTTACTCAGCAGATTAGCGACAAAATAACAGAGTTGACCAAT
ATGGTGACCAGTACCATCACTGAAAAGCTACTTAAGAACTTGATCAAGATCATATCCTCA
CTAGTTATTATAACTAGGAACTATGAAGACACCACAACAGTGCTCGCTACCCTGGCCCTT
CTTGGGTGTGATGCTTCACCATGGCAGTGGCTTAGAAAGAAAGCATGCGATGTTCTGGAG
ATACCTTATGTCATCAAGCAAGGTGACAGTTGGTTGAAGAAGTTTACTGAAGCATGCAAC
GCAGCTAAGGGACTGGAGTGGGTGTCAAACAAAATCTCAAAATTCATTGATTGGCTCAAG
GAGAAAATTATCCCACAAGCTAGAGATAAGTTGGAATTTGTAACAAAACTTAGACAACTA
GAAATGCTGGAAAACCAAATCTCAACTATACACCAATCATGCCCTAGTCAGGAACACCAG
GAAATTCTATTCAATAATGTCAGATGGTTATCCATCCAGTCTAAGAGGTTTGCCCCTCTT
TACGCAGTGGAAGCCAAAAGAATACAGAAACTAGAGCATACTATTAACAACTACATACAG
TTCAAGAGCAAACACCGTATTGAACCAGTATGTTTGCTAGTACATGGCAGCCCCGGAACA
GGTAAATCTGTAGCAACCAACCTGATTGCTAGAGCCATAGCTGAAAGAGAAAACACGTCC
ACGTACTCGCTACCCCCGGATCCATCACACTTCGACGGATACAAACAACAGGGAGTGGTG
ATTATGGACGACCTGAATCAAAACCCAGATGGTGCGGACATGAAGCTGTTCTGTCAGATG
GTATCAACAGTGGAGTTTATACCACCCATGGCATCCCTGGAGGAGAAAGGAATCCTGTTT
ACTTCAAATTACGTTCTAGCATCCACAAACTCAAGCAGAATTTCCCCCCCCACTGTGGCA
CACAGTGATGCATTAGCCAGGCGCTTTGCGTTCGACATGGACATTCAGGTCATGAATGAG
TATTCTAGAGATGGGAAATTGAACATGGCCATGGCTACTGAAATGTGTAAGAACTGTCAC
CAACCAGCAAACTTTAAGAGATGCTGTCCTTTAGTGTGTGGTAAGGCAATTCAATTAATG
GACAAATCTTCCAGAGTTAGATACAGTATTGACCAGATCACTACAATGATTATCAATGAG
AGAAACAGAAGATCCAACATTGGCAATTGTATGGAGGCTTTGTTTCAAGGACCACTCCAG
TATAAAGACTTGAAAATTGACATCAAGACGAGTCCCCCTCCTGAATGTATCAATGACTTG
CTCCAAGCAGTTGACTCCCAGGAGGTGAGAGATTACTGTGAGAAGAAGGGTTGGATAGTC
AACATCACCAGCCAGGTTCAAACAGAAAGGAACATCAACAGGGCAATGACAATTCTACAA
GCGGTGACAACCTTCGCCGCAGTGGCTGGAGTTGTCTATGTCATGTATAAACTGTTTGCT
GGACACCAGGGAGCATACACTGGTTTACCAAACAAAAAACCCAACGTGCCCACCATTCGG
ACAGCAAAGGTACAAGGACCAGGGTTCGATTACGCAGTGGCTATGGCTAAAAGAAACATT
GTTACAGCAACTACTAGCAAGGGAGAGTTCACTATGTTAGGAGTCCACGACAACGTGGCT
ATTTTACCAACCCACGCTTCACCTGGTGAAAGCATTGTGATCGATGGCAAAGAAGTGGAG
ATCTTGGATGCCAAAGCGCTCGAAGATCAAGCAGGAACCAATCTTGAAATCACTATAATC
ACTCTAAAGAGAAATGAAAAGTTCAGAGACATTAGACCACATATACCTACTCAAATCACT
GAGACAAATGATGGAGTCTTGATCGTGAACACTAGCAAGTACCCCAATATGTATGTTCCT
GTCGGTGCTGTGACTGAACAGGGATATCTAAATCTCGGTGGGCGCCAAACTGCTCGTACT
CTAATGTACAACTTTCCAACCAGAGCAGGACAGTGTGGTGGAGTCATCACATGTACTGGG
AAAGTCATCGGGATGCATGTTGGTGGGAACGGTTCACACGGGTTTGCAGCGGCCCTGAAG
CGATCATACTTCACTCAGAGTCAAGGTGAAATCCAGTGGATGAGACCTTCGAAGGAAGTG
GGATATCCAATCATAAATGCCCCGTCCAAAACCAAGCTTGAACCCAGTGCTTTCCACTAT
GTGTTTGAAGGGGTGAAGGAACCAGCAGTCCTCACTAAAAACGATCCCAGGCTTAAGACA
GACTTTGAGGAGGCAATTTTCTCCAAGTACGTGGGTAACAAAATTACTGAAGTGGATGAG
TACATGAAAGAGGCAGTAGACCACTATGCTGGCCAGCTCATGTCACTAGACATCAACACA
GAACAAATGTGCTTGGAGGATGCCATGTATGGCACTGATGGTCTAGAAGCACTTGATTTG
TCCACCAGTGCTGGCTACCCTTATGTAGCAATGGGAAAGAAGAAGAGAGACATCTTGAAC
AAACAAACCAGAGACACTAAGGAAATGCAAAAACTGCTCGACACATATGGAATCAACCTC
CCACTGGTGACTTATGTAAAGGATGAACTTAGATCCAAAACAAAGGTTGAGCAGGGGAAA
TCCAGATTAATTGAAGCTTCTAGTTTGAATGACTCAGTGGCAATGAGAATGGCTTTTGGG
AACCTATATGCTGCTTTTCACAAAAACCCAGGAGTGATAACAGGTTCAGCAGTGGGGTGC
GATCCAGATTTGTTTTGGAGCAAAATTCCGGTATTGATGGAAGAGAAGCTGTTTGCTTTT
GACTACACAGGGTATGATGCATCTCTCAGCCCTGCTTGGTTCGAGGCACTAAAGATGGTG
CTTGAGAAAATCGGATTCGGAGACAGAGTTGACTACATCGACTACCTAAACCACTCACAC
CACCTGTACAAGAATAAAACATACTGTGTCAAGGGCGGTATGCCATCTGGCTGCTCAGGC
ACTTCAATTTTTAACTCAATGATTAACAACTTGATTATCAGGACACTCTTACTGAAAACC
TACAAGGGCATAGATTTAGACCACCTAAAAATGATTGCCTATGGTGATGATGTAATTGCT
TCCTACCCCCATGAAGTTGACGCTAGTCTCCTAGCCCAATCAGGAAAAGACTATGGACTA
ACTATGACTCCAGCTGACAAATCAGCTACATTTGAAACAGTCACATGGGAGAATGTAACA
TTCTTGAAGAGATTCTTCAGGGCAGACGAGAAATACCCATTTCTTATTCATCCAGTAATG
CCAATGAAGGAAATTCATGAATCAATTAGATGGACTAAAGATCCTAGGAACACTCAGGAT
CACGTTCGCTCTCTGTGCCTTTTAGCTTGGCACAATGGCGAAGAAGAATATAACAAATTC
CTAGCTAAAATCAGGAGTGTGCCAATTGGAAGAGCTTTATTGCTCCCAGAGTACTCAACA
TTGTACCGCCGTTGGCTTGACTCATTTTAG

# Drug_Target_6_General_Function:
Involved in nucleotide binding

# Drug_Target_6_General_References:
209034	Ambros V, Baltimore D: Protein is linked to the 5' end of poliovirus RNA by a phosphodiester linkage to tyrosine. J Biol Chem. 1978 Aug 10;253(15):5263-6.
2994218	Hogle JM, Chow M, Filman DJ: Three-dimensional structure of poliovirus at 2.9 A resolution. Science. 1985 Sep 27;229(4720):1358-65.
6250717	Kitamura N, Adler CJ, Rothberg PG, Martinko J, Nathenson SG, Wimmer E: The genome-linked protein of picornaviruses. VII. Genetic mapping of poliovirus VPg by protein and RNA sequence studies. Cell. 1980 Aug;21(1):295-302.
6264310	Kitamura N, Semler BL, Rothberg PG, Larsen GR, Adler CJ, Dorner AJ, Emini EA, Hanecak R, Lee JJ, van der Werf S, Anderson CW, Wimmer E: Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature. 1981 Jun 18;291(5816):547-53.
6272282	Racaniello VR, Baltimore D: Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. Proc Natl Acad Sci U S A. 1981 Aug;78(8):4887-91.
6284987	Dorner AJ, Dorner LF, Larsen GR, Wimmer E, Anderson CW: Identification of the initiation site of poliovirus polyprotein synthesis. J Virol. 1982 Jun;42(3):1017-28.
7820548	Grant RA, Hiremath CN, Filman DJ, Syed R, Andries K, Hogle JM: Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design. Curr Biol. 1994 Sep 1;4(9):784-97.

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
2928

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
246543

# Drug_Target_6_Name:
Genome polyprotein

# Drug_Target_6_Number_of_Residues:
2209

# Drug_Target_6_PDB_ID:
1RDR

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00073	Rhv
PF00548	Peptidase_C3
PF00680	RdRP_1
PF00910	RNA_helicase
PF00947	Pico_P2A
PF01552	Pico_P2B
PF02226	Pico_P1A
PF08727	P3A

# Drug_Target_6_Protein_Sequence:
>Genome polyprotein [Contains: Capsid protein VP4
MGAQVSSQKVGAHENSNRAYGGSTINYTTINYYRDSASNAASKQDFSQDPSKFTEPIKDV
LIKTAPMLNSPNIEACGYSDRVLQLTLGNSTITTQEAANSVVAYGRWPEYLRDSEANPVD
QPTEPDVAACRFYTLDTVSWTKESRGWWWKLPDALRDMGLFGQNMYYHYLGRSGYTVHVQ
CNASKFHQGALGVFAVPEMCLAGDSNTTTMHTSYQNANPGEKGGTFTGTFTPDNNQTSPA
RRFCPVDYLLGNGTLLGNAFVFPHQIINLRTNNCATLVLPYVNSLSIDSMVKHNNWGIAI
LPLAPLNFASESSPEIPITLTIAPMCCEFNGLRNITLPRLQGLPVMNTPGSNQYLTADNF
QSPCALPEFDVTPPIDIPGEVKNMMELAEIDTMIPFDLSATKKNTMEMYRVRLSDKPHTD
DPILCLSLSPASDPRLSHTMLGEILNYYTHWAGSLKFTFLFCGFMMATGKLLVSYAPPGA
DPPKKRKEAMLGTHVIWDIGLQSSCTMVVPWISNTTYRQTIDDSFTEGGYISVFYQTRIV
VPLSTPREMDILGFVSACNDFSVRLLRDTTHIEQKALAQGLGQMLESMIDNTVRETVGAA
TSRDALPNTEASGPTHSKEIPALTAVETGATNPLVPSDTVQTRHVVQHRSRSESSIESFF
ARGACVTIMTVDNPASTTNKDKLFAVWKITYKDTVQLRRKLEFFTYSRFDMELTFVVTAN
FTETNNGHALNQVYQIMYVPPGAPVPEKWDDYTWQTSSNPSIFYTYGTAPARISVPYVGI
SNAYSHFYDGFSKVPLKDQSAALGDSLYGAASLNDFGILAVRVVNDHNPTKVTSKIRVYL
KPKHIRVWCPRPPRAVAYYGPGVDYKDGTLTPLSTKDLTTYGFGHQNKAVYTAGYKICNY
HLATQDDLQNAVNVMWSRDLLVTESRAQGTDSIARCNCNAGVYYCESRRKYYPVSFVGPT
FQYMEANNYYPARYQSHMLIGHGFASPGDCGGILRCHHGVIGIITAGGEGLVAFSDIRDL
YAYEEEAMEQGITNYIESLGAAFGSGFTQQISDKITELTNMVTSTITEKLLKNLIKIISS
LVIITRNYEDTTTVLATLALLGCDASPWQWLRKKACDVLEIPYVIKQGDSWLKKFTEACN
AAKGLEWVSNKISKFIDWLKEKIIPQARDKLEFVTKLRQLEMLENQISTIHQSCPSQEHQ
EILFNNVRWLSIQSKRFAPLYAVEAKRIQKLEHTINNYIQFKSKHRIEPVCLLVHGSPGT
GKSVATNLIARAIAERENTSTYSLPPDPSHFDGYKQQGVVIMDDLNQNPDGADMKLFCQM
VSTVEFIPPMASLEEKGILFTSNYVLASTNSSRISPPTVAHSDALARRFAFDMDIQVMNE
YSRDGKLNMAMATEMCKNCHQPANFKRCCPLVCGKAIQLMDKSSRVRYSIDQITTMIINE
RNRRSNIGNCMEALFQGPLQYKDLKIDIKTSPPPECINDLLQAVDSQEVRDYCEKKGWIV
NITSQVQTERNINRAMTILQAVTTFAAVAGVVYVMYKLFAGHQGAYTGLPNKKPNVPTIR
TAKVQGPGFDYAVAMAKRNIVTATTSKGEFTMLGVHDNVAILPTHASPGESIVIDGKEVE
ILDAKALEDQAGTNLEITIITLKRNEKFRDIRPHIPTQITETNDGVLIVNTSKYPNMYVP
VGAVTEQGYLNLGGRQTARTLMYNFPTRAGQCGGVITCTGKVIGMHVGGNGSHGFAAALK
RSYFTQSQGEIQWMRPSKEVGYPIINAPSKTKLEPSAFHYVFEGVKEPAVLTKNDPRLKT
DFEEAIFSKYVGNKITEVDEYMKEAVDHYAGQLMSLDINTEQMCLEDAMYGTDGLEALDL
STSAGYPYVAMGKKKRDILNKQTRDTKEMQKLLDTYGINLPLVTYVKDELRSKTKVEQGK
SRLIEASSLNDSVAMRMAFGNLYAAFHKNPGVITGSAVGCDPDLFWSKIPVLMEEKLFAF
DYTGYDASLSPAWFEALKMVLEKIGFGDRVDYIDYLNHSHHLYKNKTYCVKGGMPSGCSG
TSIFNSMINNLIIRTLLLKTYKGIDLDHLKMIAYGDDVIASYPHEVDASLLAQSGKDYGL
TMTPADKSATFETVTWENVTFLKRFFRADEKYPFLIHPVMPMKEIHESIRWTKDPRNTQD
HVRSLCLLAWHNGEEEYNKFLAKIRSVPIGRALLLPEYSTLYRRWLDSF

# Drug_Target_6_Reaction:
nucleoside triphosphate + RNAn = diphosphate + RNAn+1

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
RNA-directed RNA polymerase replicates genomic and antigenomic RNA by recognizing replications specific signals

# Drug_Target_6_SwissProt_ID:
P03300

# Drug_Target_6_SwissProt_Name:
POLG_POL1M

# Drug_Target_6_Synonyms:
Capsid protein VP1
Capsid protein VP2
Capsid protein VP3
Core protein P2A
Core protein P2B
Core protein P2C
Core protein P3A
EC 2.7.7.48
EC 3.4.22.28
EC 3.4.22.29
Genome polyprotein [Contains: Capsid protein VP4
Genome-linked protein VPg
P1A
P1B
P1C
P1D
P3B
P3C
P3D]
Picornain 2A
Picornain 3C
Protease 3C
RNA-directed RNA polymerase
Virion protein 1
Virion protein 2
Virion protein 3
Virion protein 4

# Drug_Target_6_Theoretical_pI:
7.13

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Nucleus

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
XRCC4

# Drug_Target_7_GenBank_ID_Gene:
U40622

# Drug_Target_7_GenBank_ID_Protein:
1151115

# Drug_Target_7_GeneCard_ID:
XRCC4

# Drug_Target_7_Gene_Name:
XRCC4

# Drug_Target_7_Gene_Sequence:
>1005 bp
ATGGAGAGAAAAATAAGCAGAATCCACCTTGTTTCTGAACCCAGTATAACTCATTTTCTA
CAAGTATCTTGGGAGAAAACACTGGAATCTGGTTTTGTTATTACACTTACTGATGGTCAT
TCAGCATGGACTGGGACAGTTTCTGAATCAGAGATTTCCCAAGAAGCTGATGACATGGCA
ATGGAAAAAGGGAAATATGTTGGTGAACTGAGAAAAGCATTGTTGTCAGGAGCAGGACCA
GCTGATGTATACACGTTTAATTTTTCTAAAGAGTCTTGTTATTTCTTCTTTGAGAAAAAC
CTGAAAGATGTCTCATTCAGACTTGGTTCCTTCAACCTAGAGAAAGTTGAAAACCCAGCT
GAAGTCATTAGAGAACTTATTTGTTATTGCTTGGACACCATTGCAGAAAATCAAGCCAAA
AATGAGCACCTGCAGAAAGAAAATGAAAGGCTTCTGAGAGATTGGAATGATGTTCAAGGA
CGATTTGAAAAATGTGTGAGTGCTAAGGAAGCTTTGGAGACTGATCTTTATAAGCGGTTT
ATTCTGGTGTTGAATGAGAAGAAAACAAAAATCAGAAGTTTGCATAATAAATTATTAAAT
GCAGCTCAAGAACGAGAAAAGGACATCAAACAAGAAGGGGAAACTGCAATCTGTTCTGAA
ATGACTGCTGACCGAGATCCAGTCTATGATGAGAGTACTGATGAGGAAAGTGAAAACCAA
ACTGATCTCTCTGGGTTGGCTTCAGCTGCTGTAAGTAAAGATGATTCCATTATTTCAAGT
CTTGATGTCACTGATATTGCACCAAGTAGAAAAAGGAGACAGCGAATGCAAAGAAATCTT
GGGACAGAACCTAAAATGGCTCCTCAGGAGAATCAGCTTCAAGAAAAGGAAAAGCCTGAT
TCTTCACTACCTGAGACGTCGAAAAAGGAGCACATCTCAGCTGAAAACATGTCTTTAGAA
ACTCTGAGAAACAGCAGCCCAGAAGACCTCTTTGATGAGATTTAA

# Drug_Target_7_General_Function:
Involved in DNA binding

# Drug_Target_7_General_References:
12509254	Hsu HL, Yannone SM, Chen DJ: Defining interactions between DNA-PK and ligase IV/XRCC4. DNA Repair (Amst). 2002 Mar 28;1(3):225-35.
12547193	Calsou P, Delteil C, Frit P, Drouet J, Salles B: Coordinated assembly of Ku and p460 subunits of the DNA-dependent protein kinase on DNA ends is necessary for XRCC4-ligase IV recruitment. J Mol Biol. 2003 Feb 7;326(1):93-103.
8548796	Li Z, Otevrel T, Gao Y, Cheng HL, Seed B, Stamato TD, Taccioli GE, Alt FW: The XRCC4 gene encodes a novel protein involved in DNA double-strand break repair and V(D)J recombination. Cell. 1995 Dec 29;83(7):1079-89.

# Drug_Target_7_HGNC_ID:
HGNC:12831

# Drug_Target_7_HPRD_ID:
15951

# Drug_Target_7_ID:
2888

# Drug_Target_7_Locus:
5q13-q14

# Drug_Target_7_Molecular_Weight:
38287

# Drug_Target_7_Name:
DNA-repair protein XRCC4

# Drug_Target_7_Number_of_Residues:
336

# Drug_Target_7_PDB_ID:
1IK9

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF06632	XRCC4

# Drug_Target_7_Protein_Sequence:
>DNA-repair protein XRCC4
MERKISRIHLVSEPSITHFLQVSWEKTLESGFVITLTDGHSAWTGTVSESEISQEADDMA
MEKGKYVGELRKALLSGAGPADVYTFNFSKESCYFFFEKNLKDVSFRLGSFNLEKVENPA
EVIRELICYCLDTIAENQAKNEHLQKENERLLRDWNDVQGRFEKCVSAKEALETDLYKRF
ILVLNEKKTKIRSLHNKLLNAAQEREKDIKQEGETAICSEMTADRDPVYDESTDEESENQ
TDLSGLASAAVSKDDSIISSLDVTDIAPSRKRRQRMQRNLGTEPKMAPQENQLQEKENSR
PDSSLPETSKKEHISAENMSLETLRNSSPEDLFDEI

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Involved in DNA nonhomologous end joining (NHEJ) required for double-strand break repair and V(D)J recombination. Binds to DNA and to DNA ligase IV (LIG4). The LIG4-XRCC4 complex is responsible for the NHEJ ligation step, and XRCC4 enhances the joining activity of LIG4. Binding of the LIG4-XRCC4 complex to DNA ends is dependent on the assembly of the DNA-dependent protein kinase complex DNA-PK to these DNA ends

# Drug_Target_7_SwissProt_ID:
Q13426

# Drug_Target_7_SwissProt_Name:
XRCC4_HUMAN

# Drug_Target_7_Synonyms:
X-ray repair cross-complementing protein 4

# Drug_Target_7_Theoretical_pI:
4.63

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Not Available

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
Not Available

# Drug_Target_8_GenBank_ID_Gene:
AE005674

# Drug_Target_8_GenBank_ID_Protein:
24054789

# Drug_Target_8_GeneCard_ID:
Not Available

# Drug_Target_8_Gene_Name:
msrA

# Drug_Target_8_Gene_Sequence:
>705 bp
TTGTGTGCAAATACGCCTCTTGTTACAACCTTAACCCCAATGACCGATTTTCGGGAGAGC
GACACCATGAGTTTATTTGATAAAAAGCATCTGGTTTCCCCCGCCGATGCCCTGCCTGGA
CGTAACACCCCGATGCCCGTAGCCACGCTGCATGCGGTCAACGGTCACTCAATGACCAAT
GTACCTGACGGAATGGAGATTGCCATTTTTGCGATGGGTTGTTTCTGGGGTGTGGAGCGT
CTGTTCTGGCAGTTACCCGGCGTTTACAGCACCGCCGCAGGCTATACCGGCGGCTATACG
CCAAATCCGACTTATCGGGAAGTGTGCTCCGGTGATACGGGTCATGCCGAAGCGGTACGC
ATTGTTTACGATCCTTCCGTCATCAGCTATGAGCAGTTGCTACAGGTATTTTGGGAGAAT
CACGATCCCGCCCAGGGAATGCGTCAGGGCAATGACCACGGCACGCAGTATCGTTCAGCG
ATTTATCCGCTGACCCCAGAACAGGATGCCGCAGCTCGCGCCAGTCTGGAACGTTTTCAG
GCGGCGATGCTTGCCGCCGATGACGATCGTCACATCACCACGGAAATCGCTAACGCCACA
CCGTTTTATTATGCCGAAGATGACCACCAGCAATATCTGCATAAAAACCCATATGGTTAT
TGTGGAATTGGCGGAATTGGCGTCTGTCTGCCGCCGGAAGCATAG

# Drug_Target_8_General_Function:
Posttranslational modification, protein turnover, chaperones

# Drug_Target_8_General_References:
12384590	Jin Q, Yuan Z, Xu J, Wang Y, Shen Y, Lu W, Wang J, Liu H, Yang J, Yang F, Zhang X, Zhang J, Yang G, Wu H, Qu D, Dong J, Sun L, Xue Y, Zhao A, Gao Y, Zhu J, Kan B, Ding K, Chen S, Cheng H, Yao Z, He B, Chen R, Ma D, Qiang B, Wen Y, Hou Y, Yu J: Genome sequence of Shigella flexneri 2a: insights into pathogenicity through comparison with genomes of Escherichia coli K12 and O157. Nucleic Acids Res. 2002 Oct 15;30(20):4432-41.
12704152	Wei J, Goldberg MB, Burland V, Venkatesan MM, Deng W, Fournier G, Mayhew GF, Plunkett G 3rd, Rose DJ, Darling A, Mau B, Perna NT, Payne SM, Runyen-Janecky LJ, Zhou S, Schwartz DC, Blattner FR: Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457T. Infect Immun. 2003 May;71(5):2775-86.

# Drug_Target_8_HGNC_ID:
Not Available

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
2939

# Drug_Target_8_Locus:
Not Available

# Drug_Target_8_Molecular_Weight:
23315

# Drug_Target_8_Name:
Peptide methionine sulfoxide reductase msrA

# Drug_Target_8_Number_of_Residues:
212

# Drug_Target_8_PDB_ID:
1FF3

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF01625	PMSR

# Drug_Target_8_Protein_Sequence:
>Peptide methionine sulfoxide reductase msrA
MSLFDKKHLVSPADALPGRNTPMPVATLHAVNGHSMTNVPDGMEIAIFAMGCFWGVERLF
WQLPGVYSTAAGYTGGYTPNPTYREVCSGDTGHAEAVRIVYDPSVISYEQLLQVFWENHD
PAQGMRQGNDHGTQYRSAIYPLTPEQDAAARASLERFQAAMLAADDDRHITTEIANATPF
YYAEDDHQQYLHKNPYGYCGIGGIGVCLPPEA

# Drug_Target_8_Reaction:
(1) peptide-L-methionine + thioredoxin disulfide + H2O = peptide-L-methionine (S)-S-oxide + thioredoxin

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
Has an important function as a repair enzyme for proteins that have been inactivated by oxidation. Catalyzes the reversible oxidation-reduction of methionine sulfoxide in proteins to methionine

# Drug_Target_8_SwissProt_ID:
P0A745

# Drug_Target_8_SwissProt_Name:
MSRA_SHIFL

# Drug_Target_8_Synonyms:
EC 1.8.4.11
Peptide Met(O
Peptide-methionine (S)-S-oxide reductase
Protein- methionine-S-oxide reductase

# Drug_Target_8_Theoretical_pI:
4.82

# Drug_Target_8_Transmembrane_Regions:
None

#END_DRUGCARD DB03963
